Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711 Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Heng, 2020, Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed/refractory acute lymphoblastic leukemia, Clin Cancer Res, 26, 1606, 10.1158/1078-0432.CCR-19-1339 Rosenbaum, 2017, Tragedy, perseverance, and chance—the story of CAR-T therapy, N Engl J Med, 377 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 10.1126/scitranslmed.3002842 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Zhou, 2020, Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-hodgkin lymphomas, Front Immunol, 11, 3034, 10.3389/fimmu.2020.564099 Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497 Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med, 24, 20, 10.1038/nm.4441 Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547 Jacoby, 2016, CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity, Nat Commun, 7, 1, 10.1038/ncomms12320 Morgan, 2020, Use of cell and genome modification technologies to generate improved “off-the-shelf” CAR T and CAR NK Cells, Front Immunol, 11, 1965, 10.3389/fimmu.2020.01965 Mueller, 2017, Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, Blood, 130, 2317, 10.1182/blood-2017-06-786129 Shah, 2019, Mechanisms of resistance to CAR T cell therapy, Nat Rev Clin Oncol, 16, 372 Ghorashian, 2019, Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR, Nat Med, 25, 1408, 10.1038/s41591-019-0549-5 Turtle, 2016, CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Yan, 2019, A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial, Lancet Haematol, 6, e521, 10.1016/S2352-3026(19)30115-2 Pan, 2020, Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL, Blood, 135, 387, 10.1182/blood.2019003293 Sutherland, 2020, Modular chimeric antigen receptor systems for universal CAR T cell retargeting, Int J Mol Sci, 21, 7222, 10.3390/ijms21197222 Chow, 2020, Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy, Blood Adv., 4, 4869, 10.1182/bloodadvances.2020002292 Libert, 2020, Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy, Leukemia, 34, 3064, 10.1038/s41375-020-0760-x Mikhailova, 2021, Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease, Br J Haematol, 193, 602, 10.1111/bjh.17382 Rabilloud, 2021, Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy, Nat Commun, 12, 1, 10.1038/s41467-021-21168-6 Pehlivan, 2018, CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease, Curr Hematol Malig Rep, 13, 396, 10.1007/s11899-018-0470-x Shah, 2019, Multi targeted CAR-T cell therapies for B-cell malignancies, Front Oncol, 9, 146, 10.3389/fonc.2019.00146 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Kotani, 2018, Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes, Blood, 132, 2047, 10.1182/blood-2018-99-115351 Gardner, 2018, Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy, Blood, 132, 10.1182/blood-2018-99-117493 Fesnak, 2016, Engineered T cells: the promise and challenges of cancer immunotherapy, Nat Rev Cancer, 16, 566, 10.1038/nrc.2016.97 Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet North Am Ed, 385, 517, 10.1016/S0140-6736(14)61403-3 Van Der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat Rev Drug Discovery, 14, 499, 10.1038/nrd4597 Zhao, 2015, Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004 Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838 Wherry, 2007, Molecular signature of CD8+ T cell exhaustion during chronic viral infection, Immunity, 27, 670, 10.1016/j.immuni.2007.09.006 Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol, 15, 486, 10.1038/nri3862 Han, 2017, Adnectin-based design of chimeric antigen receptor for T cell engineering, Mol Ther, 25, 2466, 10.1016/j.ymthe.2017.07.009 Lam, 2020, Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains, Nat Commun, 11, 1 Gardner R, Finney O, Smithers H, Leger KJ, Annesley CE, Summers C et al. (American Society of Hematology Washington, DC, 2016). Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020 Majzner, 2017, Harnessing the immunotherapy revolution for the treatment of childhood cancers, Cancer Cell, 31, 476, 10.1016/j.ccell.2017.03.002 Fischer, 2017, CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis, J Immunother, 40, 187, 10.1097/CJI.0000000000000169 Nagel, 2017, Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy, Blood, 130, 2027, 10.1182/blood-2017-05-782888 Zoghbi, 2017, Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement, Pediatr. Blood Cancer, 64, e26594, 10.1002/pbc.26594 Orlando, 2018, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat Med, 24, 1504, 10.1038/s41591-018-0146-z Kailayangiri, 2020, Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers, Cancers, 12, 1075, 10.3390/cancers12051075 Watanabe, 2015, Target antigen density governs the efficacy of anti–CD20-CD28-CD3 ζ chimeric antigen receptor–modified effector CD8+ T cells, J Immunol, 194, 911, 10.4049/jimmunol.1402346 Hombach, 2016, Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack, Mol Ther, 24, 1423, 10.1038/mt.2016.82 Hamieh, 2019, CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape, Nature, 568, 112, 10.1038/s41586-019-1054-1 Choi, 2019, CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity, Nat Biotechnol, 37, 1049, 10.1038/s41587-019-0192-1 O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9, 10.1126/scitranslmed.aaa0984 Walker, 2017, Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase, Mol Ther, 25, 2189, 10.1016/j.ymthe.2017.06.008 Yoshida, 2016, All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia, Clin Transl Immunol, 5, e116, 10.1038/cti.2016.73 Ramakrishna, 2019, Modulation of target antigen density improves CAR T-cell functionality and persistence, Clin Cancer Res, 25, 5329, 10.1158/1078-0432.CCR-18-3784 Biberacher, 2012, The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion, Haematologica, 97, 771, 10.3324/haematol.2011.049155 Ramakrishna, 2017, Modulation of CD22 antigen density improves efficacy of CD22 chimeric antigen receptor (CAR) T cells against CD22lo B-lineage leukemia and lymphoma, Blood, 130 Chim, 2018, Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond, Leukemia, 32, 252, 10.1038/leu.2017.329 Goldschmidt, 2019, Navigating the treatment landscape in multiple myeloma: which combinations to use and when?, Ann Hematol, 98, 1, 10.1007/s00277-018-3546-8 Kumar, 2019, Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing, Blood, 133, 652, 10.1182/blood-2018-08-825349 Brudno, 2018, T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma, J Clin Oncol, 36, 2267, 10.1200/JCO.2018.77.8084 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Zhao, 2018, A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma, J Hematol Oncol, 11, 1, 10.1186/s13045-018-0681-6 Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520 Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res, 1, 26, 10.1158/2326-6066.CIR-13-0006 Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells, Sci Transl Med, 8, 10.1126/scitranslmed.aaf8621 Alabanza, 2017, Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains, Mol Ther, 25, 2452, 10.1016/j.ymthe.2017.07.013 Sommermeyer, 2017, Fully human CD19-specific chimeric antigen receptors for T-cell therapy, Leukemia, 31, 2191, 10.1038/leu.2017.57 Holliger, 2005, Engineered antibody fragments and the rise of single domains, Nat Biotechnol, 23, 1126, 10.1038/nbt1142 Zheng, 2021, Optimization of CAR-T cell-based therapies using small-molecule-based safety switches, J Med Chem, 64, 9577, 10.1021/acs.jmedchem.0c02054 Lundh, 2020, Next-generation CAR T cells to overcome current drawbacks, Int J Hematol, 1 Lee III DW, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B et al. (American Society of Hematology Washington, DC, 2016). Chu, 2018, Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer, Biosci Trends, 10.5582/bst.2018.01048 Kim, 2015, Redirection of genetically engineered CAR-T cells using bifunctional small molecules, J Am Chem Soc, 137, 2832, 10.1021/jacs.5b00106 Lu, 2019, Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies, Front Oncol, 9, 151, 10.3389/fonc.2019.00151 Low PS, Luo Q, Napoleon JV, Zhang B, in Cancer Res. (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …, 2020), vol. 80. Sahillioglu, 2021, CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function, Cancer Immunol Res, 9, 999, 10.1158/2326-6066.CIR-21-0095 Chen, 2018, Increasing T cell versatility with SUPRA CARs, Cell, 173, 1316, 10.1016/j.cell.2018.05.030 Cho, 2018, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses, Cell, 173, 1426, 10.1016/j.cell.2018.03.038 Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc Natl Acad Sci, 113, E459, 10.1073/pnas.1524155113 Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J, 6, 10.1038/bcj.2016.61 Pishali Bejestani, 2017, Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model, Oncoimmunology, 6, 10.1080/2162402X.2017.1342909 Gardner, 2018, Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia, Blood, 132, 10.1182/blood-2018-99-113126 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Shalabi, 2018, Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma, Haematologica, 103, e215, 10.3324/haematol.2017.183459 Yu, 2017, Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma, Am J Hematol, 92, E11, 10.1002/ajh.24594 Qin, 2018, Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22, Mol Ther, 11, 127 Brossart, 2020, The role of antigen spreading in the efficacy of immunotherapies, Clin Cancer Res, 26, 4442, 10.1158/1078-0432.CCR-20-0305 Khalil, 2016, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Nat Rev Clin Oncol, 13, 273, 10.1038/nrclinonc.2016.25 Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Philipson, 2020, 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling, Sci Signal, 13, 10.1126/scisignal.aay8248 Song, 2011, In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB), Cancer Res, 71, 4617, 10.1158/0008-5472.CAN-11-0422 Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021 Enblad, 2018, A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia, Clin Cancer Res, 24, 6185, 10.1158/1078-0432.CCR-18-0426 Guercio, 2021, CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells, Haematologica, 106, 987, 10.3324/haematol.2019.231183 Ying, 2019, Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s lymphoma, Mol Ther, 15, 60 Gargett, 2016, GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade, Mol Ther, 24, 1135, 10.1038/mt.2016.63 Heczey, 2017, CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma, Mol Ther, 25, 2214, 10.1016/j.ymthe.2017.05.012 Li, 2017, Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors, Clin Cancer Res, 23, 6982, 10.1158/1078-0432.CCR-17-0867 Niu, 2021, Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: a case report, World J Clin Cases, 9, 2394, 10.12998/wjcc.v9.i10.2394 Jaspers, 2017, Development of CAR T cells designed to improve antitumor efficacy and safety, Pharmacol Ther, 178, 83, 10.1016/j.pharmthera.2017.03.012 Song, 2019, Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies, Int J Mol Sci, 20, 5010, 10.3390/ijms20205010 Armitage, 1992, Molecular and biological characterization of a murine ligand for CD40, Nature, 357, 80, 10.1038/357080a0 Schönbeck, 2001, The CD40/CD154 receptor/ligand dyadRID=“†” ID=“†” review, Cell Mol Life Sci CMLS, 58, 4, 10.1007/PL00000776 Kuhn, 2019, CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response, Cancer Cell, 35, 10.1016/j.ccell.2019.02.006 Park, 2018, A Phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL armored CAR T cells in patients with relapsed or refractory NHL and CLL including Richter’s transformation, Blood, 132, 10.1182/blood-2018-99-117737 Yeku, 2016, Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy, Biochem Soc Trans, 44, 412, 10.1042/BST20150291 Koneru, 2015, A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer, J Transl Med, 13, 1, 10.1186/s12967-015-0460-x Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044 Adachi, 2018, IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor, Nat Biotechnol, 36, 346, 10.1038/nbt.4086 Maude, 2015, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood, 125, 4017, 10.1182/blood-2014-12-580068 Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med, 24, 563, 10.1038/s41591-018-0010-1 Kagoya, 2018, A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects, Nat Med, 24, 352, 10.1038/nm.4478 Nobles, 2020, CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration, J Clin Invest, 130, 673, 10.1172/JCI130144 Carty, 2018, The loss of TET2 promotes CD8+ T cell memory differentiation, J Immunol, 200, 82, 10.4049/jimmunol.1700559 Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z Tyrakis, 2016, S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate, Nature, 540, 236, 10.1038/nature20165 Delgoffe, 2021, The role of exhaustion in CAR T cell therapy, Cancer Cell, 39, 885, 10.1016/j.ccell.2021.06.012 Lynn, 2019, c-Jun overexpression in CAR T cells induces exhaustion resistance, Nature, 576, 293, 10.1038/s41586-019-1805-z Seo, 2021, BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells, Nat Immunol, 1 Rostamian, 2021, A metabolic switch to memory CAR T cells: Implications for cancer treatment, Cancer Lett, 500, 107, 10.1016/j.canlet.2020.12.004 Martinez, 2019, CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment, Front Immunol, 10, 128, 10.3389/fimmu.2019.00128 Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability, J Clin Invest, 129, 2123, 10.1172/JCI125423 Pan, 2019, CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia, Leukemia, 33, 2854, 10.1038/s41375-019-0488-7 Bhoj, 2016, Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy, Blood, 128, 360, 10.1182/blood-2016-01-694356 Curran, 2019, Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL, Blood, 134, 2361, 10.1182/blood.2019001641 Kebriaei, 2016, Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest, 126, 3363, 10.1172/JCI86721